Evidence map›Paper›PMID 24280450›Full record

ArticleOncotarget2013

Evaluation of zinc (II) chelators for inhibiting p53-mediated apoptosis.

Akinori Morita, Shinya Ariyasu, Soichiro Ohya, Ippei Takahashi, Bing Wang, Kaoru Tanaka, Takatoshi Uchida, Haruna Okazaki, Kengo Hanaya, Atsushi Enomoto and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targets for protection and mitigation of radiation injury.Cellular and molecular life sciences : CMLS · 2020
    Review
  5. Biomolecules · 2020
    Article
  6. Antioxidants (Basel, Switzerland) · 2019
    Article
  7. Review
  8. TAp73 promotes anabolism.Oncotarget · 2014
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Akinori MoritaDepartment of Radiological Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
Shinya Ariyasu
Soichiro Ohya
Ippei Takahashi
Bing Wang
Kaoru Tanaka
Takatoshi Uchida
Haruna Okazaki
Kengo Hanaya
Atsushi Enomoto
Mitsuru Nenoi
Masahiko Ikekita
Shin Aoki
Yoshio Hosoi
Tokyo University of Science · JPHiroshima University · JPThe University of Tokyo · JPTokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a previous study, we reported that sodium orthovanadate (vanadate) is the first known inhibitor that is capable of protecting mice from death from the radiation-induced gastrointestinal syndrome via its ability to block both transcription-dependent and transcription-independent p53 apoptotic pathways. In this paper, we report that vanadate has a unique activity for inducing the denaturation of p53 relative to other known radioprotective p53 inhibitors, pifithrin-α (PFTα) and pifithrin-µ (PFTµ). This potent radioprotective effect of vanadate prompted us to undertake a more extensive search for p53 inhibitors that can induce p53 denaturation. Based on the fact that p53 denaturation can be induced by the dissociation of a zinc ion, which is used as a structural factor of p53, we screened some zinc (II) chelators for the suppression of the DNA binding activity of p53 in vitro and the inhibition of radiation-induced p53-dependent apoptosis in MOLT-4 cells. The findings indicate that two of five zinc (II) chelators also suppressed apoptosis. Among the inhibitors tested, Bispicen (N,N'-Bis(2-pyridylmethyl)-1,2-ethanediamine) had the highest inhibition activity. A mechanistic study using cells bearing different p53 status or functions (i.e., p53-knockdown MOLT-4 transformant and its revertants, p53 mutant cells, p53-null cells), and p53-independent apoptotic stimuli revealed that the suppressive effect of Bispicen on apoptosis is specifically mediated through p53. Moreover, Bispicen, similar to vanadate, induces the denaturation of p53 as well as the blocking of both transcription-dependent and -independent apoptotic pathways. Our findings indicate that the use of zinc (II) chelators represent a new approach for protecting against radiation-induced p53-dependent apoptosis through the inhibition of p53-dependent apoptotic pathways.

Indexed as

AnimalsApoptosisCations, DivalentCell Line, TransformedCell Line, TumorChelating AgentsMiceProtein DenaturationRadiation-Protective AgentsTumor Suppressor Protein p53VanadatesZincCations, DivalentChelating AgentsRadiation-Protective AgentsTumor Suppressor Protein p53VanadatesZinc

Identifiers

PMID24280450
PMCPMC3926839
OpenAlexW2146465911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.